Sumitomo Dainippon Pharma Annual Report 2017
4/102

We achieved record-high net sales and operating income.Additionally, acquisition activities enhanced our pipeline in the areas of Psychiatry & Neurology, as well as Oncology,while we made strategic growth investments for when the exclusivity period of LATUDA® expires.From April 2015, we started a ONE TEAM operating structure for the Global Clinical Development (GCD) organization, which unifies Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals Inc. Under this cooperative structure, we are pursuing GCD that allows simultaneous new drug application submission in Japan and the U.S., while accelerating development of late-stage development products.Accelerateddevelopment of late-stagedevelopment productsSnapshot 201603Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#4

このブックを見る